Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 588 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR What to Know About Using Activated Charcoal During Cancer December 21, 2023 EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin August 18, 2025 Finally Pregnant After Struggling With Infertility For Years, She Was Diagnosed... October 25, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib February 1, 2021 Load more HOT NEWS Pursuing precision medicine in a flagship lung cancer trial ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After... Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to...
